Affordable Access

deepdyve-link
Publisher Website

Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.

Authors
  • Gupta, Anubha1
  • Jarzab, Barbara2
  • Capdevila, Jaume3
  • Shumaker, Robert4
  • Hussein, Ziad1
  • 1 Eisai Limited, Hatfield, UK.
  • 2 Department of Nuclear Medicine and Institute of Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland. , (Poland)
  • 3 Medical Oncology Department, Hospital Vall d'Hebrón, Barcelona, Spain. , (Spain)
  • 4 Eisai Inc., Woodcliff Lake, NJ, USA.
Type
Published Article
Journal
British Journal of Clinical Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
June 2016
Volume
81
Issue
6
Pages
1124–1133
Identifiers
DOI: 10.1111/bcp.12907
PMID: 26879594
Source
Medline
Keywords
License
Unknown

Abstract

The significant effects of several covariates on lenvatinib PK variability were small in magnitude, and therefore were not considered clinically relevant, or to warrant any dose adjustment.

Report this publication

Statistics

Seen <100 times